MirimGene Co., Ltd.

10:45 AM - 11:00 AM (PDT), Tuesday, June 14, 2022
MirimGene’s target of focus includes WARS among human aminoacyl-tRNA synthetases (ARSs). Especially, WARS, called tryptophanyl- tRNA synthetase secreted from monocytes is proved as a primary defense system against infection based upon Nature Microbiology. If hyperactivated WARS is blocked, autoimmune diseases including Rheumatoid Arthritis, Atopic Dermatitis and Inflammatory Bowel Disease can be treated based upon POC data in animals. If the reduced WARS in immunesuppressive patients is activated, varous infectious disease like sepsis and tuberculosis could be cure from hypo-immune status. MrimGene's antibody biologics have been developed based upon POC data in animals and upstream/downstream-processed in collaboration with SamSung Biologics. in 2023, GLP data are due to be generated and the application of IND for Clinical Phase 1 trial is expected at the beginning of 2024.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2019
Main Therapeutic Focus:
Lead Product in Development:
Antibody against Rheumatoid Arthritis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
photo
Vice President
MirimGene Co. Ltd.